Key Highlights
- Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) surged about 42.5 percent to USD 4.59 on October 5, 2026 in published data, with no single company announcement confirmed as the trigger for the full move.
- At about 1.51 million shares outstanding after a 1-for-10 reverse split on July 24, 2026, simple arithmetic puts the Market Value near USD 6.9 million at USD 4.59.
- Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) named Eric Sherb chief financial officer on October 1 at a USD 60,000 annual base salary, after interim CFO Erick Frim resigned on September 29.
- The shares jumped 120 percent on September 24 after a MindWave blockchain agreement and fell 22.46 percent on September 29, so Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) has swung wildly in under two weeks.
A Tiny Float and a Big Swing
Published data show Apimeds closing up about 42.5 percent at USD 4.59 on October 5, 2026, a larger gain than the roughly 31 percent seen midday near USD 4.23. The company disclosed in an 8-K that interim chief financial officer Erick Frim resigned on September 29 with no disagreement, and that Eric Sherb, a certified public Accountant who had been fractional CFO of Subsidiary MindWave Innovations, took the role on October 1. No filing dated October 5 was found, so the day's gain cannot be tied to one announcement. With about 1.51 million shares, small orders can move the price sharply, and a market value near USD 6.9 million is smaller than many private companies.
Biotech Roots and a Blockchain Pivot
Apimeds licenses Apitox, an intradermal bee-venom therapy used in South Korea since 2003 for osteoarthritis pain, and plans a second US Phase 3 trial designed to meet Food and Drug Administration standards. The company merged with MindWave, an AI and blockchain unit, announced in December 2025 alongside a USD 100 million private placement. MindWave signed a 12-month AQUAEChain agreement that pays fees plus 20 percent of credits issued, and a 12-month FlashChain deal paid partly in tokens and shares, with no disclosed dollar values. A settlement of a dispute with Inscobee was reached in May 2026. This mix explains why the shares react to blockchain headlines, not only to clinical news.
Risks and What to Watch
Apimeds has no product Revenue and reported a six-month 2026 net loss of USD 55.23 million, including a second-quarter loss of USD 20.17 million. Compensation from blockchain contracts is paid in tokens and shares whose values were not disclosed, and the second Phase 3 trial has no confirmed start date or funding. The shares have traded between USD 1.51 and USD 59.70 over 52 weeks per published data, a range that signals extreme volatility. Investors should watch for 8-K filings, a permanent finance team, trial funding and any share issuance, which could dilute holders. Heavy buying in tiny stocks can reverse quickly, and the company is not a candidate for most mainstream portfolios.
Where Things Stand
The bee-venom biotech that surged 42.5 percent to USD 4.59 is Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS), and the move coincides with a CFO change and blockchain headlines without a confirmed single cause. Its drug is early, losses are large and the share count is tiny, so prices can swing violently. Company filings, not price action, are the reliable guide to what comes next, and readers should treat the October 5 jump with caution until the company explains it.


_11_13_2026_19_32_11_765725.jpg)



Please wait processing your request...